DOI: 10.6084/m9.figshare.9636983.v1
title: Data related to treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: systematic review and meta-analysis

description: This data archive contains the following 7 files relating to treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: <b>- Supplementary figure 1:</b> Thematic map exploring strategies for treatment optimisation. The duration, combination and/or dose of a treatment regimen is optimised for the individual receiving therapy. Abbreviations: RBV - ribavirin; DAA - direct-acting antiviral; IFN - interferon.<br> <b>- Supplementary figure 2:</b> Cochrane risk of bias tool for randomised controlled trials summary - review authors' judgements about each risk of bias item for each included study. Prepared using Cochrane Review Manager v5.3 (RevMan, RRID:SCR_003581). <b>- Supplementary figure 3:</b> Risk of bias graph - review authors' judgements about each risk of bias item presented as percentages across all included studies. Prepared using Cochrane Review Manager v5.3 (RevMan, RRID:SCR_003581). <b>- Prisma 2009 Checklist: </b>Completed checklist providing page numbers in the associated manuscript for the location of each element of the Prisma 2009 checklist. <b>- HCV Treatment Optimisation Stata .do file: </b>This is the .do file used to process and analyse the data. The proprietary statistical software 'Stata' was used to create this file. <b>- HCV Treatment Optimisation Meta-analysis Data Sheet: </b>This is the data extracted from trials included in this meta-analysis. The file was imported into Stata for analysis using the included .do file.<b>- Supplementary Tables 1-6.docx:</b>This single Word document contains the following 6 tables: - Supplementary table 1: Summary of Ovid search strategy - Medline and Embase. Last conducted on 4<sup>th</sup> July 2019. - Supplementary table 2: Individual study characteristics. The factors used for stratification or personalisation, treatment strategy adopted, and resultant SVR rates (intention-to-treat and per protocol) are presented for each treatment arm. - Supplementary table 3: Meta-regression - ‘maintain SVR group’. Clinical and methodological variables were subject to univariable random effects meta-regression. Only those variables with p≤0·1 on univariable analysis were carried forward to the multivariable model. Significance of variables in multivariable model taken at p≤0·05 level. Upper (UCI) and lower (LCI) 95% confidence intervals are presented. - Supplementary table 4: Meta-regression - improve SVR group. Clinical and methodological variables were subject to univariable random effects meta-regression. There were no significant associations and therefore a multivariable model was not constructed. Upper (UCI) and lower (LCI) 95% confidence intervals are presented. - Supplementary table 5: Modified Newcastle Ottawa Scale for quality assessment of nonrandomised studies. In this modified scale, a study can be awarded a maximum of one star for each item within the Selection and Outcome categories. The comparability domain was removed to account for the non-comparative nature of included studies (unmodified version can be found at: http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf). - Supplementary table 6: Ongoing randomised controlled trials that are evaluating stratified or personalised treatment strategies.<br>The associated study is a systematic review and meta-analysis which explores the impact of treatment optimisation strategies, such as stratified medicine or personalised medicine, in our current era of direct-acting antiviral therapy, applied to the treatment of hepatitis C virus.